Filter posts

A Very Big BTK January

We all heard reports that January was a great start to 2012 for the stock …

Reviewing the drug class of 2011

The drug class of 2011 was larger than the past few graduating classes. We count …

Venture Capital increases in 2011, but...

The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture …

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …

IPO Update - Jan 2012

2011 ended quietly for the US biotech IPO market. It has now been almost two …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

Just how big is $11 Billion? GILD Acquires VRUS

Seeing the markets open down 2% or more on a Monday morning feels like “business …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Biotech IPO Window - Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue …